British cannabis oil is the leading private Cannabidol brand in the UK. British Cannabishas been approved for a total number of 310 products The Food Standards Agency (FSA) released a list earlier this month.
The Berkshire-based firm received preliminary approval for 75 of its products alone, and the 235 submitted together with other companies. FSA approved 3,536 products as new or “novel foods” according to the listing, released March 31.
RX Pharmatech Ltd. (Bradford, West Yorkshire), which has ties with U.S. This was the second highest total RX Pharmatech submitted 11 products by itself and 157 with other producers.
According to the Association for the Cannabinoid Industry. (ACI), the UK market for CBD products was worth PS690million. According to ACI, CBD sales in the UK more than doubled between 2019 and 2021, this makes the UK the second-largest consumer market outside of the USA.
The FSA approved products for 374 companies. Some companies applied separately; others were only participants in joint applications filed with other producers. Other companies also filed independent applications. Others filed jointly and independently. There were 70 CBD applications submitted to the FSA.
Products that were on the list may still be available for sale. However, products that did not pass FSA scrutiny must be removed from market. FSA stressed that approvals are preliminary, some products may be removed during the later stages of their review.
Many of these products were promoted to pre-validation status (“awaiting proof”), the second phase of FSA’s novel product approval process. FSA has now approved 57 products from five companies.
FSA’s novel approval process for food is first and foremost designed to clarify the grey market in CBD that has seen thousands more cannabidol products pop up in shops over the years. FSA guidelines stipulate those products in distribution must have been available before February 13, 2020. Products introduced after that date would not be eligible for consideration.
BRITISH CANNABIS products were presumably obtained from a consortium established by the ACI. ACI said this week that it is still analyzing FSA lists and refused to reveal information about the total number of products it received through its consortium, or the names of the companies involved in the submissions (FPs). ACI has at least 628 products that were developed by members, including British Cannabis.
Applications of EIHA
RX Pharmatech’s products were submitted separately by the European Industrial Hemp Association, which saw 1,992 CBD product preliminarily approved.
EIHA Projects GmbH submitted products from 193 companies. The EIHA saw 1,992 CBD products preliminarily approve, accounting for about 56%.. They were included in EIHA Applications covering isolates (1.157), and full spectrum extracteds (835).
A quick look at the top companies
There were 374 companies involved in the entire list of 3,536 products, here are five top-five based on the number approved by FSA.
British Cannabis was established in 2015. It is an independent, vertically integrated producer and distributor of cannabis, CBD, and other cannabinoid-rich products.The company supplies white-label brands with its own brand products. BRITISH CANNABIS maintains a research farm in Portugal and has its own lab, manufacturing plant, warehouse, and dispatch operations. According to the company, it shipped over 50,000 CBD oils to its largest white label clients in the first half 2021, these clients are unidentified but are known as “two of industry’s most well-known brands”. British Cannabis announced in September 2021 it was planning to invest in a new facility. It will include an ISO-accredited cannabis analytics testing lab and a cosmetics line. This could increase its potential capacity by up to three times. It is one of 35 UK testing labs responsible for the “chemist trial” assessment that measures CBD and cannabinoid contents in commercial products.
Associated principals : Thomas Whettem CEO & Founder, David Ralston, Managing director
RX Pharmatech Ltd
RX Pharmatech Ltd. doesn’t appear to have a website, and very little public information about it is available Based on other sources, the company was founded in May 2016. RX Pharmatech is a supplier for bulk isolates, and distillates manufactured by GVB Biopharma in Las Vegas, Nevada, USA. RX Pharmatech was also a party the second-highest FSA product list. GVB, Las Vegas, Nevada, USA, claimed in a Press Release April 7, 2020 that it is also the largest supplier to producers of white-label formulations for oral vape liquids. GVB stated that it sources raw materials from an American farmers cooperative. GVB’s website indicates that there is a UK office located in Doncaster, Yorkshire. GVB only has one investor, Decathlon Capital Partners GVB’s website indicates that there is a UK office located in Doncaster, Yorkshire. GVB only has one investor, Decathlon Capital Partners. GVB claims that it has operations in Europe (unidentified location) and Bogota, Colombia. GVB Biopharma joined Medicaleaf Ltd. and Cheltenham, Gloucestershire as part of its partnership with RX Pharmatech to submit three products to the FSA. GVB Biopharma is said to be in an strategic relationship with Sonder Fulfillment. Sonder Fulfillment is a division Golden Triangle Ventures’ penny stock provider.
Principals associated with RX Pharmatech Ltd. Dominic James Bartle is the director and Damien Jonathan Bove is the director. GVB Biopharma Phillip Swindells is the CEO and co-founder. Jack Feldman is president & Co-founder. Hugh Kinsman is CFO.
Mile High Labs
Mile High Labs in Broomfield, Colorado is a supplier for CBD, CBN and CBG. Mile High reported that in 2019, it raised $100 million through two rounds of funding, including $65 million from MGG Investment Group, New York (2019). Mile High uses raw materials sourced from the USA’s contracted CBD hemp growers to create an extraction facility. According to its website, the company also has a Belfast, Northern Ireland office.
Associated principals Jonathan Hilley CEO, Ryan Keeler COO, Jodi Gatica VP Quality, Danny Moses, Investor.
Taylor Mammon Ltd
Taylor Mammon Ltd. claims to be a white-label manufacturer, and cannabidol distributor. It is located in Welwyn Garden City. The parent company is based in Kentucky and operates under the name of OGGUSA Inc. GenCanna crashed in 2020 when it filed bankruptcy amid a series of lawsuits from creditors who claimed that the company owed them between $100 and 500 million. There were a lot of creditors who claimed the company owed them between $100 to 500 million. In May 2020 the bankruptcy court approved GenCanna’s sale to MGG Investment Group, New York. GenCanna bought Taylor Mammon, and UK-based CBD Capital last year.
Associated principals : Taylor Mammon – Alex Taylor, cofounder; James Taylor chief commercial officer; Nathan Wogman cofounder and managing director. GenCanna/OGGUSA Inc. – Andrew Barnett, CEO; Hassan Akhtar, managing director, Europe.
Sativa Wellness Group
Although now called Goodbody Health Inc, it submitted its novel foods applications as Sativa Wellness. This Canada-based company makes OTC traded cannabidol products This includes oils, capsules, and gummies There are also laboratories in the UK and Poland for testing CBD products.There is also a branch in Beckington in Somerset, England. In 2020, the company suffered a loss of almost $6.5 million (PS5 millions) according to public financial reports. Goodbody shares are currently trading at approximately $0.05 (5cents). Goodbody’s UK subsidiary, PhytoVista Laboratories (April 2022) was granted a controlled-drug license.
Associated principals (Goodbody Health Inc.): Geremy Tom, Founder & Executive Chair; Marc Howells CEO; Anne Tew CFO and Corporate Secretary.